BRCA1

Overview

BRCA1 (breast cancer type 1 susceptibility protein) is a human tumor suppressor gene that encodes a protein essential for the maintenance of genomic stability. BRCA1 functions primarily in the repair of DNA double-strand breaks through homologous recombination repair (HRR), and it also participates in DNA damage signaling, cell-cycle checkpoint control, chromatin regulation, and transcriptional responses to genotoxic stress. Loss of BRCA1 function impairs accurate DNA repair and promotes genomic instability, which underlies its central role in hereditary breast and ovarian cancer predisposition.

Clinically, pathogenic BRCA1 variants are associated with increased lifetime risk of breast and ovarian cancer and are also relevant in other tumor types where homologous recombination deficiency influences treatment response. BRCA1 status is therefore used as a biomarker for DNA repair defects and for sensitivity to therapies such as PARP inhibitors, including olaparib and other poly(adenosine diphosphate ribose) polymerase inhibitors. In recent research, BRCA1 has also been examined in relation to tumor microenvironment features, metabolic phenotypes, and therapeutic vulnerabilities in Cancers such as lung adenocarcinoma, pancreatic cancer, colorectal cancer, and breast cancer.

Recent Publications Summary

Recent publications on BRCA1 have focused on its role as a germline or somatic alteration in cancer biology, treatment response, and clinical decision-making. In a case discussed at the WIN International Molecular tumor Board, a 48-year-old woman with a BRCA1 germline mutation developed multiple primary Cancers, including breast, skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel cancer, illustrating the complex longitudinal management of BRCA1-associated cancer predisposition 42478852Jul. In hereditary breast cancer cohorts, BRCA1/2-related genomic instability was further examined through whole-genome, methylome, and transcriptome analyses, with homologous recombination-deficient tumors showing promoter hypermethylation and loss of heterozygosity at BRCA1/2, alongside distinct molecular subtypes with different immune and stromal features 41991965Apr.

Several studies evaluated how BRCA1 status may influence treatment selection and therapeutic response. In metastatic breast cancer with bone metastases, denosumab was associated with longer real-world progression-free survival in germline BRCA1/2-mutated HR+/HER2-negative patients receiving CDK4/6 inhibitors, supporting interest in RANKL/RANK signaling pathway modulation in this setting 41921366Apr. In high-grade serous ovarian carcinoma, investigators explored whether malignant ascites could serve as an alternative specimen for BRCA1/2 next-generation sequencing, reflecting the clinical importance of BRCA1 testing at diagnosis for guiding PARP inhibitor use 42046206Apr. A phase II trial also examined niraparib in advanced pancreatic cancer harboring pathogenic variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2, extending PARP inhibitor research beyond the classic BRCA1/2-mutated populations 41686836Feb.

Other publications addressed BRCA1 in the context of immune biology, DNA damage response, and broader clinical management. In lung adenocarcinoma, BRCA1/2 somatic mutations were associated with increased genomic instability and poor prognosis, yet also with better outcomes after immune checkpoint blockade; specifically, BRCA1 mutations correlated with an upregulated type I IFN/IFN-γ signature and CD8+ T cell activation 42189716May. In colorectal cancer models, fatty acid synthase (FASN) inhibition impaired DNA damage response signaling by decreasing BRCA1 and ATM recruitment to γH2AX foci, thereby enhancing chemotherapy-induced DNA damage and creating synthetic lethality with PARP inhibition 41661672Feb. Additional studies examined metabolic differences in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants, ipsilateral breast tumor recurrence and prognosis after breast-conserving surgery, and factors influencing uptake of risk-reducing mastectomy among unaffected BRCA1/BRCA2 carriers, underscoring the ongoing clinical relevance of BRCA1 across prevention, surveillance, and treatment decisions 42132994May42133182May42126651May.

What Changes, What Holds

1. BRCA1-associated cancer predisposition now appears to require long-term, multi-organ surveillance
REINFORCES The case-based report does not alter the core account of BRCA1 as a hereditary cancer predisposition gene, but it sharpens the clinical implication that carriers may develop multiple primary tumors across a lifetime and therefore need ongoing, broad surveillance rather than organ-specific follow-up alone 42478852Jul. The multi-omics cohort work also reinforces the established link between BRCA1/2 loss and homologous recombination deficiency, while adding molecular detail about promoter hypermethylation, loss of heterozygosity, and immune/stromal subtype differences 41991965Apr.

2. BRCA1 testing remains clinically actionable, but the best specimen and the breadth of PARP-inhibitor use are still being worked out
REINFORCES These studies extend the established role of BRCA1 status as a biomarker for treatment selection by supporting testing at diagnosis and by exploring alternative specimens when standard tissue is limited 42046206Apr. The pancreatic cancer trial also keeps BRCA1 within the broader homologous recombination-deficient population relevant to PARP inhibition, but it does not displace the baseline view; instead, it suggests that clinical utility may extend beyond classic breast and ovarian settings 41686836Feb. The denosumab finding is adjacent rather than transformative 41921366Apr.

3. BRCA1 status may also predict immune responsiveness and interact with DNA-damage targeting strategies outside the classic hereditary-cancer frame
NEW DIRECTION The lung adenocarcinoma and colorectal cancer studies move beyond the Overview’s focus on BRCA1 as a repair-defect biomarker in hereditary breast and ovarian cancer, showing that BRCA1/2 alterations can shape immune signatures, prognosis, and synthetic-lethal combinations in other tumors 42189716May41661672Feb. That broadens BRCA1 from a predisposition and PARP-sensitivity marker into a potential modifier of immunotherapy and combination-treatment response, although these are correlative or preclinical findings that still need prospective validation. The prevention and surgery-related studies mainly reinforce ongoing clinical relevance 42132994May42133182May42126651May.

Overview update candidates: BRCA1-associated Cancers may require long-term multi-organ surveillance; BRCA1 testing may be feasible from malignant ascites when standard tissue is limited; BRCA1/2 alterations may help identify tumors with immune-checkpoint sensitivity or synthetic-lethal vulnerabilities beyond the classic breast/ovarian setting.